<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540344</url>
  </required_header>
  <id_info>
    <org_study_id>24/06/2009</org_study_id>
    <secondary_id>2009-014040-11</secondary_id>
    <nct_id>NCT01540344</nct_id>
  </id_info>
  <brief_title>Combined Anticancer Treatment of Advanced Colon Cancer</brief_title>
  <acronym>COMBATAC</acronym>
  <official_title>Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of
      perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and
      bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal
      carcinomatosis arising from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 10% of patients with colorectal cancer (CRC) already show peritoneal carcinomatosis
      at the time of initial diagnosis and up to 25% of all patients develop peritoneal
      carcinomatosis during the natural course of their disease as a common sign of tumor
      progression or recurrence.

      The existing data suggests that CRS and HIPEC as an integral part of a multidisciplinary
      treatment concept may improve long-term survival of selected patients with peritoneal
      carcinomatosis of colonic origin. Moreover, hyperthermic peritoneal perfusion with
      oxaliplatin in combination with synchronous application of 5-FU/leucovorin seems to improve
      the efficacy of HIPEC in comparison to a mitomycin C-based intraperitoneal treatment regimen
      and may lead to a better local tumor control. The improved systemic treatment strategy with
      neoadjuvant chemotherapy may lead to increased rates of complete macroscopic cytoreduction
      and together with the adjuvant treatment to better control of distant metastasis and tumor
      recurrence. However, there is no prospective study available evaluating the clinical and
      oncological outcome after standard-of-care chemotherapy including targeted anticancer therapy
      in combination with CRS and HIPEC. The published morbidity and mortality rates after CRS and
      HIPEC are comparable to other major gastrointestinal surgery and seem to be acceptable
      considering the expected improvement of oncological outcome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the combined treatment concept</measure>
    <time_frame>9 months</time_frame>
    <description>Assessment of tumor progression, AE and SAE during treatment phase leading to modification or end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by EORTC-QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathohistological regression</measure>
    <time_frame>16 weeks</time_frame>
    <description>assessed by Dworak grade of regression in histology after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX/FOLFIRI + cetuximab (6 cycles)
CRS and HIPEC
FOLFOX/FOLFIRI + cetuximab (6 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRS</intervention_name>
    <description>complete macroscopic cytoreduction (CC-0/1)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Cytoreductive surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Hyperthermic intraperitoneal chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Synchronous or metachronous peritoneal carcinomatosis arising from histologically
             proven colorectal or appendiceal adenocarcinoma

          -  Complete macroscopic cytoreduction (CCR-0/1)

          -  Free treatment interval of at least 6 month after the last chemotherapy

          -  Age over 18 and below 71 years

          -  Good general health status (Karnofsky &gt; 70%, ECOG 0-2)

          -  Absence of hematogenous metastasis (lung, bone, brain, &gt; 3 peripheric resectable liver
             metastases)

          -  Absence of contraindication for systemic chemotherapy and/or extended surgery

          -  Life expectancy greater than 6 months

          -  Written informed consent

          -  Creatinine clearance &gt; 50 ml/min, serum creatinine ≤ 1.5 x ULN

          -  Serum bilirubin ≤ 1.5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2.5 x ULN

          -  Platelet count &gt; 100,000 /ml, haemoglobin &gt; 9 g/dl, neutrophile granulocytes ≥ 1,500
             /ml, International Normalized Ration (INR) ≤ 2

          -  Absence of peripheral neuropathy &gt; grade 1 (CTCAE v4.0)

          -  No pregnancy or breast feeding. Adequate contraception in fertile patients.

        Exclusion Criteria:

          -  Incomplete cytoreduction

          -  Hematogenous metastasis including irresectable liver metastasis

          -  Prior chemotherapy or therapy with EGFR receptor antibody for metastatic disease

          -  K-ras mutation

          -  Known allergy to murine or chimeric monoclonal antibodies

          -  Histology of signet ring carcinoma

          -  Other malignancy than disease under study / second cancer

          -  Impaired liver, renal or hematologic function as mentioned above (inclusion criteria)

          -  Heart failure NYHA ≥ 2 or significant Coronary Artery Disease

          -  Alcohol and/or drug abuse

          -  Patients unable or unwilling to comply with the study protocol, treatment or follow-up

          -  Patients included in other clinical trials interfering with the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pompiliu Piso, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Mitte, Humboldt-University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Friedrich-Alexander-University Erlangen- Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cologne-Merheim Medical Center, University Witten/Herdecke</name>
      <address>
        <city>Koeln</city>
        <zip>51058</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of God Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Wuerzburg, Julius-Maximilians University</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013 Feb 7;13:67. doi: 10.1186/1471-2407-13-67.</citation>
    <PMID>23391248</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Pompiliu Piso, Prof. MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>peritoneal carcinomatosis</keyword>
  <keyword>cytoreductive surgery</keyword>
  <keyword>HIPEC</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

